Clinical Scorecard: Consensus from Delphi Method on Practical Implementation of Revised Migraine Diagnosis and Treatment Guidelines in the Asia-Pacific Region
At a Glance
Category
Detail
Condition
Migraine
Key Mechanisms
ICHD-3 criteria for diagnosis; anti-CGRP mAbs for treatment.
Target Population
Adults and adolescents (13-17 years) in the Asia-Pacific region.
Care Setting
Clinical settings involving headache specialists.
Key Highlights
Consensus reached on 12 of 21 statements regarding migraine management.
93% of participants used ICHD-3 for diagnosis; 79% found it easy to apply.
86% considered anti-CGRP mAbs effective for migraine prevention.
Efficacy, safety, and tolerability are primary factors in treatment selection.
Participants advised against using anti-CGRP mAbs in children under 12.
Guideline-Based Recommendations
Diagnosis
Utilize ICHD-3 criteria for accurate migraine diagnosis.
Evaluate migraine-related disability and associated symptoms.
Management
Consider anti-CGRP mAbs as first-line treatment for chronic or episodic migraine.
Monitoring & Follow-up
Use headache diaries, MIDAS, and HIT-6 for assessment.
Risks
Insufficient evidence for the use of anti-CGRP mAbs in children under 12.
Patient & Prescribing Data
Adults and adolescents (13-17 years) in the Asia-Pacific region.
Efficacy is the primary deciding factor in selecting anti-CGRP mAbs.
Clinical Best Practices
Adopt standardized criteria for diagnosis to improve accuracy.
Address unmet needs in migraine management through effective treatment options.
by Charles Hua Chiang Siow, Shengyuan Yu, Surat Tanprawate, Shuu-Jiun Wang, Elspeth J. Hutton, Byung-Kun Kim, Min Kyung Chu, Norihiro Suzuki, Wanakorn Rattanawong, Ka Sing Wong, Mi Ji Lee, Zhao Dong, Hebo Wang, Xianliang Li, Koichi Hirata, Takao Takeshima
The nurse practitioner profession claims the No. 1 spot across three categories in the U.S. News & World Report 2026 Best Jobs rankings for the third consecutive year.
